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OBJECTIVE—The clinical effectiveness of parenterally-admin-
istered glucagon-like peptide-1 (GLP-1) mimetics to improve
glucose control in patients suffering from type 2 diabetes strongly
supports discovery pursuits aimed at identifying and developing
orally active, small molecule GLP-1 receptor agonists. The pur-
pose of these studies was to identify and characterize novel
nonpeptide agonists of the GLP-1 receptor.
RESEARCH DESIGN AND METHODS—Screening using cells
expressing the GLP-1 receptor and insulin secretion assays with
rodent and human islets were used to identify novel molecules.
The intravenous glucose tolerance test (IVGTT) and hyperglyce-
mic clamp characterized the insulinotropic effects of compounds
in vivo.
RESULTS—Novel low molecular weight pyrimidine-based com-
pounds that activate the GLP-1 receptor and stimulate glucose-
dependent insulin secretion are described. These molecules
induce GLP-1 receptor-mediated cAMP signaling in HEK293 cells
expressing the GLP-1 receptor and increase insulin secretion
from rodent islets in a dose-dependent manner. The compounds
activate GLP-1 receptor signaling, both alone or in an additive
fashion when combined with the endogenous GLP-1 peptide;
however, these agonists do not compete with radiolabeled GLP-1
in receptor-binding assays. In vivo studies using the IVGTT and
the hyperglycemic clamp in Sprague Dawley rats demonstrate
increased insulin secretion in compound-treated animals. Fur-
ther, perifusion assays with human islets isolated from a donor
with type 2 diabetes show near-normalization of insulin secretion
upon compound treatment.
CONCLUSIONS—These studies characterize the insulinotropic
effects of an early-stage, small molecule GLP-1 receptor agonist
and provide compelling evidence to support pharmaceutical
optimization. Diabetes 59:3099–3107, 2010
H
yperglucagonemia and dysregulation of insulin
secretion impair postprandial glucose ho-
meostasis and thus are central to the pathogen-
esis of type 2 diabetes. Impairment of the
incretin effect, including reduced secretion of glucagon-
like peptide-1 (GLP-1) (1,2), is implicated in the progres-
sion of pancreatic islet dysfunction in type 2 diabetic
patients. Development and use of incretin-based therapeu-
tics may, therefore, be an effective strategy to restore
normal islet function by providing insulinotropic and
glucagon-suppressive capabilities. In recent years, clinical
studies have shown that replacement therapy with meta-
bolically stable GLP-1 mimetics greatly improves manage-
ment of hyperglycemia, nearly correcting blood glucose
regulation for some patients. For example, treatment with
either exenatide or liraglutide reduces fasting hyperglyce-
mia and results in sustained lowering of glycosylated A1C
(A1C) levels (3,4). In addition, these therapies often re-
duce body weight and improve several cardiovascular
parameters (5,6). Unfortunately, both of these GLP-1 ana-
logues are peptides requiring administration by subcuta-
neous injection.
The GLP-1 receptor is a member of the class B/II family
of seven transmembrane G protein-coupled receptors
(GPCRs) that include receptors for peptide hormones
such as secretin, GLP-1, glucose-dependent insulinotropic
polypeptide (GIP), glucagon, vasoactive intestinal peptide
(VIP), corticotropin-releasing factor (CRF), calcitonin, and
parathyroid hormone (PTH) (7–9). Historically, the discov-
ery of nonpeptide agonists of these receptors that could
enable development of orally active pharmaceuticals has
been generally unsuccessful. To a large extent, this difﬁ-
culty has been attributed to the mechanisms used by class
B GPCRs to recognize ligands and induce signaling. Inter-
action of endogenous peptide hormones with their recep-
tors typically involves large receptor:ligand binding sites
and is often initiated by receptor NH2-terminal ectodo-
mains (ECDs). This extracellular structure interacts with
COOH-terminal residues of cognate ligands and positions
the NH2-terminus of the ligand to interact with critical
determinants in receptor transmembrane regions, thereby
activating heterotrimeric G-proteins and subsequently ad-
enylyl cyclase (10–12).
The recent reports describing GLP-1 receptor activation
by a series of substituted quinoxalines (13–16) and a
cyclobutane derivative (17) suggest that it may be possible
to develop nonpeptide GLP-1 receptor agonists. Both
scaffolds activate GLP-1 receptor signaling in heterologous
From
1Endocrine Discovery, Lilly Research Laboratories, Eli Lilly and Com-
pany, Indianapolis, Indiana;
2Lead Generation and Optimization Biology,
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana;
and
3Discovery Chemistry Research and Technologies, Lilly Research
Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
Corresponding author: Kyle W. Sloop, sloop_kyle_w@lilly.com.
Received 14 May 2010 and accepted 23 August 2010. Published ahead of
print at http://diabetes.diabetesjournals.org on 7 September 2010. DOI:
10.2337/db10-0689.
M.B.B. is currently afﬁliated with Pﬁzer, Inc., Groton, Connecticut.
© 2010 by the American Diabetes Association. Readers may use this article as
long as the work is properly cited, the use is educational and not for proﬁt,
and the work is not altered. See http://creativecommons.org/licenses/by
-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page
charges. This article must therefore be hereby marked “advertisement” in accordance
with 18 U.S.C. Section 1734 solely to indicate this fact.
ORIGINAL ARTICLE
diabetes.diabetesjournals.org DIABETES, VOL. 59, DECEMBER 2010 3099GLP-1 receptor-expressing cellular systems, and the qui-
noxalines clearly induce glucose-stimulated insulin secre-
tion in vitro from rodent islets and ex vivo via perfused
pancreas (13,16). We now report novel, low molecular
weight pyrimidines that activate the GLP-1 receptor to
induce glucose-dependent insulin secretion both in vitro
and in vivo. These molecules may offer therapeutic advan-
tage because of the ability of the compounds to act alone
or in combination with GLP-1. Further, these agonists
nearly restore insulin secretion to normal in human dia-
betic islets.
RESEARCH DESIGN AND METHODS
Measurement of luciferase. HEK293 cells stably expressing human GLP-1
receptor and a 3x-CRE luciferase reporter were grown at 37°C in 5% CO2 in
Dulbecco’s modiﬁed Eagle’s medium-31053 (Invitrogen, Carlsbad, CA) supple-
mented with 0.5% FBS, 2 mmol/l L-glutamine, 50 units/ml penicillin, 50 g/ml
streptomycin, and 20 mmol/l HEPES. For compound testing, cells were plated
into 96-well poly-D-lysine, white opaque microplates. Compounds were solu-
bilized in DMSO, diluted in medium containing 0.1% BSA fraction V substi-
tuted for 0.5% FBS, and added to cells. After a 5-h incubation, cells were
harvested in Steadylite plus lysis reagent (Perkin Elmer, Waltham, MA), and
luciferase activity was measured according to the manufacturer’s instructions
using an Envision 2104 multilabel reader. Data are expressed as a percentage
of maximum stimulation induced by the GLP-1 (7–36) amide peptide (Bachem,
Torrance, CA).
Measurement of cAMP. HEK293 cells stably expressing human GLP-1
receptor were used for measurement of intracellular cAMP. Two hours before
compound testing, cells were resuspended in the aforementioned medium and
plated in 96-well half area, solid black microplates. Compounds were then
added to cells as described above. Following a 20-min incubation, cells were
assayed for cAMP using the cAMP dynamic 2 kit with homogenous time-
resolved ﬂuorescence technology (Cisbio, Bedford, MA). Fluorescence was
measured according to the manufacturer’s instructions using an Envision
2,104 Multilabel Reader. Data are expressed as nM cAMP of the ﬁnal assay
solution induced by the GLP-1 receptor agonists.
Animal care, IVGTT, and hyperglycemic clamp studies. Animals were
maintained in accordance with the Institutional Animal Use and Care Com-
mittee of Eli Lilly and Company and the Guide for the Use and Care of
Laboratory Animals by the National Institutes of Health. For animal treat-
ment, compounds were solubilized in dosing solution containing 10% ethanol/
solutol, 20% polyethylene glycol-400, and 70% PBS (pH 7.4).
The IVGTT studies were performed as previously described (18). Male SD
rats were purchased from Harlan (Indianapolis, IN) and group-housed three
per cage in polycarbonate cages with ﬁlter tops. Rats were maintained on a
12:12 h light-dark cycle (lights on at 6:00 A.M.) at 21°C and received 2014
Teklad Global diet (Harlan, Indianapolis) and deionized water ad libitum. Rats
were fasted overnight and anesthetized with 60 mg/kg pentobarbital (Lund-
beck, Deerﬁeld, IL) for the duration of the experiment. For glucose and
compound administration, a catheter with a diameter of 0.84 mm (Braintree
Scientiﬁc, Braintree, IL) was inserted into the jugular vein. For rapid blood
collection, a larger catheter with 1.02-mm diameter (Braintree Scientiﬁc,
Braintree, IL) was inserted into the carotid artery. Blood was collected for
glucose and insulin levels at time 0, 2, 4, 6, 10, and 20 min after intravenous
administration of the compound which was immediately followed by an
intravenous glucose bolus of 0.5 g/kg. Plasma levels of glucose were deter-
mined using a Hitachi 912 clinical chemistry analyzer (Roche, Indianapolis,
IN). Plasma insulin was determined using an electrochemiluminescence assay
(Meso Scale, Gaithersburg, MD).
For the hyperglycemic clamp, SD rats were purchased from Taconic with
surgically implanted femoral artery and vein catheters. After an overnight fast,
an initial blood sample was taken at time 0 from the arterial catheter, followed
by compound administration via the venous catheter. Subsequently, glucose
infusion via the venous catheter was initiated, and the infusion rates were
varied to maintain a blood glucose concentration of 250 mg/dl throughout
the experiment. Blood samples were collected every 5 min for glucose and
every 10 min for insulin measurements over the course of 1 h. Blood samples
were collected in EDTA tubes. Glucose concentrations were determined using
an Accucheck Advantage Glucometer (Roche Diagnostics, Indianapolis, IN),
and insulin was measured using an electrochemiluminescence assay for rat
insulin (Meso Scale, Gaithersburg, MD).
Islet isolation and insulin secretion. Male SD rats weighing 300 g were
killed by CO2 asphyxiation and subsequent cervical dislocation. The common
bile duct was cannulated with a 27-gauge needle, and the pancreas was
distended with 10 ml of Hank’s balanced salt solution buffer ([ HBSS], Sigma,
St. Louis, MO) containing 2% BSA (Applichem, Boca Raton, FL) and 1 mg/ml
collagenase (Sigma, St. Louis, MO). Subsequently, the pancreas was removed
and digested in HBSS at 37°C. Islets were puriﬁed on a Histopaque (His-
topaque-1077: Histopaque-11991 mixture, Sigma, St. Louis, MO) gradient for 18
min at 750g. Islets were cultured overnight in RPMI-1640 medium containing
10% FBS, 100 units/ml penicillin, and 100 g/ml streptomycin (Invitrogen,
Carlsbad, CA). Human islets from healthy donors were purchased from Prodo
Laboratories (Irvine, CA). Human islets from a donor with type 2 diabetes (a
59-year-old male who died of a cerebrovascular stroke; islets were harvested
on the day of his death, cultured overnight, and shipped the next day) were
obtained from Asterand (Detroit, MI). Human islets were cultured overnight
as described above. Islet perifusion experiments were carried out in a
buffered, temperature controlled perifusion system as previously described
(19,20). Brieﬂy, groups of 20 islets were placed in reaction chambers and
perifused with Earle’s balanced salt solution (EBSS) supplemented with 10
mmol/l HEPES and 3.3 mmol/l glucose for 20–40 min. The glucose concen-
tration in the perifusion buffer was then raised to 16.7 mmol/l to stimulate
insulin secretion. Compounds were added to the perifusion buffer as
indicated.
Insulin secretion in static incubation experiments was measured in EBSS
(Invitrogen, Carlsbad, CA). Islets were incubated in EBSS containing 2.8
mmol/l glucose at 37°C for 30 min. Groups of three size-matched islets were
then hand picked and incubated in 0.3 ml of EBSS containing the indicated
amount of glucose and compounds at 37°C for 90 min. Subsequent to the
perifusion and static incubation experiments, supernatants and perifusates
were collected and stored at 20°C until assayed for insulin using a
commercially available electrochemiluminescence assay (Meso Scale, Gaith-
ersburg, MD).
Statistics. In vivo and islet data are represented as mean  SEM and were
compared using ANOVA followed by Dunnett test. Repeated measures anal-
ysis of variance was used to assess the statistical signiﬁcance between time
courses. The null hypothesis was rejected at P  0.05.
RESULTS
Identiﬁcation of low molecular weight GLP-1 recep-
tor agonists. Since identiﬁcation of small molecule acti-
vators of class B GPCRs remains largely elusive, we
surmised that assessment of additional chemical space
associated with several literature reports of GLP-1 recep-
tor agonists (13,17,21–23) would provide a more rational
group of molecules for evaluation versus high throughput
screening. Accordingly, a series of three-dimensional phar-
macophore models was created, leading to the identiﬁca-
tion of a small (2000 compound) library gleaned from a
variety of internal and commercial sources. This library
was designed to assess key hypotheses associated with
novel chemical space aiming to identify new GLP-1 recep-
tor ligands. Compound A (Fig. 1A) was discovered via
screening of this library using HEK293 cells stably cotrans-
fected with the human GLP-1 receptor (NM_002062) and a
3X-cAMP response element (CRE) luciferase reporter.
Compound A, which is commercially available (CAS reg-
istry number: 870083-94-6), increased luciferase in GLP-1
receptor HEK293 cells, but was inactive in parent HEK293
cells. Compound A displayed an EC50 value of 1.6 mol/l
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FIG. 1. The chemical structures of two pyrimidine-based GLP-1 recep-
tor agonists, compound A (A) and compound B (B) are depicted.
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GLP-1 (Fig. 2A). Although this compound represented a
viable starting point with moderate in vitro activity and
some insulinotropic capability in ex vivo rat islet assays,
structural modiﬁcations were introduced to improve po-
tency to warrant in vivo studies. Through examination of
the various regions of the molecule, Compound B (Fig. 1B)
with a benzyloxy substituent introduced onto the phenyl
ring of compound A in the meta position, along with
deletion of the chlorine atom and a change of the oxida-
tion state of the sulfur from sulfone to sulfoxide, resulted
in an improved EC50 value of 0.66 mol/l and 99% efﬁcacy
(similar data were obtained using the rat GLP-1 receptor;
EC50  0.755 mol/l, 85% efﬁcacy of maximum GLP-1).
Neither compound A nor compound B were active in cells
expressing the GLP-2, GIP, PTH, or glucagon receptors
(Fig. 2D and data not shown).
Key structural differences between the pyrimidine series
and the quinoxalines reported by Knudsen et al. (13) are
evident. The pyrimidines reported here require both the
triﬂuoromethyl and sulfonyl groups for high activity and
an electron deﬁcient heterocycle, whereas the quinoxa-
line-based GLP-1 receptor agonists require one or the
other of these functional groups and a more electron-rich
ring system. The optimized quinoxaline contains an addi-
tional electron donating t-butylamine function, providing
an even more electron-rich heterocyclic ring and an addi-
tional hydrogen bond donor, not seen with these pyrimi-
dines, whose H bond characteristics are considerably
different both in nature and position. Finally, although not
to the extent reported for the quinoxalines (13), it should
be noted that high concentrations of compound A or
compound B display lower signaling in the in vitro assays.
Compound B also showed activity in rat and human
islets (Figs. 3B and 7A–C, respectively), enabling in vivo
proﬁling of the compound. Additional details of the struc-
ture-activity relationship will be published in due course.
To further evaluate compound B, assays were performed
using the GLP-1 receptor peptide antagonist, exendin 9-39
(exendin-49-39) (24,25). This competitive antagonist binds
the GLP-1 receptor ECD, but lacks the amino acids needed
for interaction with extracellular loop regions to induce
intracellular signaling (25,26). Treatment of GLP-1 recep-
tor expressing HEK293 cells with exendin 9-39 blunted
GLP-1 activity; however, the antagonist had no inhibitory
effect on compound B-induced GLP-1 receptor signaling
(Fig. 2B). These results suggest compound B activates the
GLP-1 receptor via a different mechanism than native
GLP-1. Consistent with these ﬁndings, compound B was
unable to displace [
125I] GLP-1 binding to cell membranes
expressing the human GLP-1 receptor (data not shown).
Additional in vitro studies were performed to further
evaluate the mechanistic differences between GLP-1 and
compound B using a modiﬁed form of the GLP-1 receptor
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FIG. 2. Low molecular weight GLP-1 receptor agonists activate GLP-1 receptor signaling. A: Compound A and compound B induced GLP-1
receptor-mediated signaling in HEK293 cells coexpressing the human GLP-1 receptor and a 3x-cAMP response element-luciferase reporter, but
were not active in cells lacking the GLP-1 receptor. In the human GLP-1 receptor HEK293 cells, the EC50 values for compounds A and B were 1.6
mol/l and 0.66 mol/l, respectively; data are presented as percentages of stimulation of a maximum concentration of human GLP-1. B: The
competitive GLP-1 receptor peptide antagonist exendin (9-39) blunted GLP-1 peptide activity but did not reduce compound B-induced signaling.
C: Compound B was active in HEK293 cells expressing a modiﬁed form of the GLP-1 receptor lacking the NH2-terminal ECD (–ECD-GLP-1
receptor); the native GLP-1 peptide had no effect in cells expressing the –ECD-GLP-1 receptor. D: Compound B was not active in HEK293 cells
expressing the glucagon-like peptide-2 receptor (GLP-2R), glucose-dependent insulinotropic polypeptide receptor (GIP-R), glucagon receptor
(GCG-R), or parathyroid hormone receptor (PTH-R).
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1–138; referred to as –ECD-GLP-1 receptor). In line with
the established requirement of the ECD for GLP-1 binding
and receptor activation, GLP-1 (tested at concentrations
as high as 300 nmol/l) was not active in cells expressing
the –ECD-GLP-1 receptor (Fig. 2C); however, compound
B did show activation of the truncated receptor (Fig. 2C),
indicating the ECD is not required to induce GLP-1 recep-
tor signaling by this small molecule. Based on these
results, compound B likely interacts with an allosteric site
proximal to or within the GLP-1 receptor transmembrane
domains. A similar hypothesis was proposed previously
for the quinoxaline series of GLP-1 receptor agonists
(13,16).
Glucose-dependent insulin secretion in SD rat islets
by a GLP-1 receptor low molecular weight agonist.
GLP-1 is a glucose-dependent insulinotropic peptide
(27,28). Accordingly, bona ﬁde nonpeptide GLP-1 receptor
agonist compounds would be predicted to act as insulin
secretagogues only in conditions of elevated glucose con-
centrations. To evaluate these properties, static incuba-
tions of pancreatic islets isolated from SD rats were used.
In low glucose (2.8 mmol/l), neither GLP-1 nor compound
B increased the concentration of insulin secreted into the
media after a 90-min incubation. In these conditions,
however, treatment of islets with the sulfonylurea gliben-
clamide (glyburide) caused a fourfold increase in insulin
levels (Fig. 3A). In islet experiments using high glucose
concentrations (11.2 mmol/l), GLP-1 demonstrated insuli-
notropic activity, and compound B caused a robust, con-
centration-dependent increase in insulin secretion (Fig.
3B). The ability of compound B to speciﬁcally induce
cAMP-mediated signaling in GLP-1 expressing cells, in
combination with its glucose-dependent insulinotropic ac-
tivity, supports the conclusion that compound B is a GLP-1
receptor agonist.
GLP-1 and compound B have additive mechanisms.
Development of a low molecular weight GLP-1 receptor
agonist that is efﬁcacious in combination with endogenous
GLP-1 or therapeutic GLP-1 mimetics may offer advan-
tages such as improved efﬁcacy and ﬂexibility with com-
bination treatment regimens for type 2 diabetes. Data on
compound B indicate this molecule is a GLP-1 receptor
agonist that does not compete with native GLP-1 and likely
interacts with an allosteric site to activate the GLP-1
receptor (see above). Therefore, experiments were under-
taken to evaluate the activity of compound B in the
presence of the GLP-1 peptide. For these studies, a cAMP
assay using GLP-1 receptor expressing HEK293 cells and
an insulin secretion assay in cultured pancreatic islets
isolated from SD rats were used. Coincubation of com-
pound B with various concentrations of GLP-1 induced
both cAMP production (Fig. 4A) and insulin secretion (Fig.
4B) in an additive manner. The observation that com-
pound B potentiates GLP-1 action supports exploring
further optimization of these pyrimidine-based com-
pounds as a novel treatment for type 2 diabetes.
Stimulation of insulin secretion in SD rats. To explore
the in vivo insulinotropic effects of compound B, glucose-
stimulated insulin secretion was measured in compound-
treated SD rats undergoing an IVGTT and a hyperglycemic
clamp. In both models, compound B induced insulin
secretion over the time course of the glucose challenge
(Figs. 5 and 6). In the IVGTT, fasted-SD rats implanted
with dual cannulas were anesthetized and administered
via a jugular vein cannula either vehicle, GLP-1 (dosed at
10 g/kg), or compound B (dosed at 10 mg/kg) immedi-
ately followed by a bolus of glucose (administered at 0.5
g/kg). Blood samples were drawn from the carotid artery
cannula for measurement of glucose (Fig. 5A) and insulin
(Fig. 5B) levels at times 0, 2, 4, 6, 10, and 20 min. Both
GLP-1 and compound B displayed insulin secretagogue
activity in this experimental model (Fig. 5B). Insulin
output is reported as incremental area under the curve
(AUC) of plasma insulin concentrations during the 20-min
time course. Compared with vehicle, animals dosed with
compound B exhibited a threefold elevation in insulin
AUC, whereas GLP-1 treatment increased insulin by four-
fold (Fig. 5C). Although the IVGTT model demonstrated
signiﬁcant increases in circulating levels of insulin, robust
changes in plasma glucose were not induced by compound
B treatment. This result is likely caused by anesthesia-
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FIG. 3. Compound B increases glucose-dependent insulin secretion from SD rat islets. A: Insulin concentrations from static cultures of SD rat
islets incubated in media containing low glucose (2.8 mmol/l) and either GLP-1 (100 nmol/l), compound B (3 mol/l), or the sulfonylurea
glibenclamide (5 mol/l). B: Insulin concentrations from static cultures of SD rat islets incubated in media containing high glucose (11.2 mmol/l)
and either GLP-1 (100 nmol/l) or various concentrations of compound B (0.3–10 mol/l). All islet treatments were performed for 90 min. Results
are expressed as mean  SEM, *P < 0.05.
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only very potent insulinotropic molecules, such as the
GLP-1 peptide, induce a statistically signiﬁcant change in
glucose (unpublished data). Therefore, we further as-
sessed the glucodynamic effects of compound B in the
more sensitive (nonanesthetized SD rats) hyperglycemic
clamp model that enables evaluation of changes in insulin
and glucose over a longer time course. Compound B
(dosed at 10 mg/kg) or vehicle was administered to
animals as a single intravenous dose at the beginning of
the experiment. Intravenous infusion of glucose main-
tained blood glucose concentrations at 250 mg/dl (Fig.
6A). Compound B-treated animals required 20% higher
glucose infusion rates to maintain this glucose level (Fig.
6B). Measurement of serum insulin concentrations over
the next 60 min demonstrated higher insulin levels in
compound B-treated animals compared with vehicle con-
trols (Fig. 6C), with the AUC20–60 min calculation showing
an 83% increase (Fig. 6D). The insulin secretory response
induced by compound B observed using both the IVGTT
and hyperglycemic clamp methods is consistent with
pharmacology demonstrated by peptide GLP-1 receptor
agonists (29) and supports the results obtained from the
islet assays showing that compound B is a glucose-depen-
dent insulin secretagogue. Because oral dosing of com-
pound B failed to show insulinotropic effects similar to
those achieved by intravenous administration, additional
optimization of compound B is required to improve the
pharmacokinetic properties of the molecule to enable
longer-term in vivo testing that will allow evaluation of
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FIG. 5. Compound B increases plasma insulin levels in the SD rat IVGTT model. Time course of plasma (A) glucose and (B) insulin concentrations
in fasted, anesthetized animals treated with either vehicle (f), GLP-1 () (10 g/kg), or compound B (E) (dosed at 10 mg/kg) immediately before
intravenous administration of a glucose bolus (0.5 g/kg). Results are expressed as mean  SEM. C: AUC of the insulin excursion curves for vehicle
versus the GLP-1 or compound B treatment groups, *P < 0.05.
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and toxicity.
Stimulation of insulin secretion from normal and
diabetic human islets by compound B. To increase the
probability of successfully developing novel glucose-de-
pendent insulin secretagogues for the treatment of type 2
diabetes, ex vivo insulin secretion assays using human
pancreatic islets are sometimes conducted. Similar to the
insulinotropic effects in rodent islets, compound B stimu-
lated glucose-dependent insulin release from human islets.
Static cultures of islets from a healthy donor incubated
with various concentrations of compound B showed in-
creased insulin levels (Fig. 7A). Further, we established a
perifusion system for compound testing using human
islets. In this system, reaction chambers containing islets
from a healthy individual were perifused ﬁrst with media
containing low glucose (3.3 mmol/l) followed by perifusate
containing high glucose (16.7 mmol/l). For islets treated
with media containing compound B, insulin levels were
higher compared with controls over the time course (Fig.
7B) with total insulin AUC increased by twofold. Similar
experiments were performed with islets harvested from a
donor who had suffered from type 2 diabetes. In these
assays, treatment with compound B again caused an
increase in insulin release into the media (Fig. 7C; insulin
AUC increased by twofold). Comparison of results from
the perifusion studies indicates that the increase in insulin
secretion from diabetic islets achieved by compound B
approached 50% of that observed with high glucose treat-
ment of islets from the healthy donor. The observed
insulin secretory properties of compound B in human
islets from both normal and diabetic individuals demon-
strates that application of the compound selection and
preclinical testing scheme used here can result in the
discovery of novel GLP-1 receptor low molecular weight
agonists.
DISCUSSION
Class B GPCRs typically are activated by endocrine pep-
tide hormones such as GLP-1, GIP, glucagon, PTH, VIP,
secretin, CRF, and calcitonin (7–9). Accordingly, class B
GPCRs represent some of the most attractive targets for
therapeutic intervention, and this is borne out by regula-
tory approval of several large molecule biotherapeutics,
including PTH (teriparatide, Forteo) for osteoporosis,
exendin-4 (exenatide, Byetta) and liraglutide (Victoza) for
type 2 diabetes, and calcitonin (calcitonin-salmon, Miacal-
cin) for Paget disease, hypercalcemia, and osteoporosis
(12). Unfortunately, there has been much difﬁculty identi-
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FIG. 6. Compound B increases plasma insulin levels in the SD rat hyperglycemic clamp model. A: Intravenous dosing with vehicle (f) or 10 mg/kg
compound B (E) occurred immediately before intravenous infusion of glucose. Glucose levels measured from venous blood every 5 min are shown.
Results are expressed as mean  SEM. B: Blood glucose concentrations of 250 mg/dl were maintained throughout the experiment by varying the
glucose infusion rates. C: Time course of plasma insulin concentrations in fasted animals treated with either vehicle (f) or compound B (E).
Results are expressed as mean  SEM. D: AUC20–60 min of the insulin secretion for vehicle (ﬁlled bar) versus compound B-treated (open bar)
animals, *P < 0.05.
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that activate class B GPCRs. The inability to modulate the
activity of class B GPCRs by traditional small molecule
approaches likely is caused by the unique structural
architecture and activation mechanism used by these
GPCRs. Ligands to these receptors typically are 30–40
amino acids in size and bind via a two-step mechanism
(10–12). The initial binding event is an interaction be-
tween the COOH-terminal amino acids of ligand peptides
and the ECD of class B GPCRs. The second phase of
receptor activation is the interaction of the NH2-terminal
residues of the ligand with transmembrane domains of the
receptor to induce an activated conformation (10–12). It
appears that the main functions of the GLP-1 receptor
ECD are to confer peptide selectivity and act as a high
afﬁnity binding site for the peptide ligand. This unique
mechanism of activation of class B GPCRs likely has
hindered conventional screening approaches for this
target.
Recently, substantial progress was made in the genera-
tion of antagonists for several class B GPCRs, including
the glucagon, PTH, CGRP, and CRF receptors (12,30).
Small molecule antagonists of class B GPCRs have been
characterized as either orthosteric antagonists or negative
allosteric modulators. In contrast, minimal success has
been achieved in the discovery of class B small molecule
agonists; isolated examples include the discovery of small
molecule agonists of the PTH receptor (31), the calcitonin
receptor (32,33), and the CRF receptor (34). With the
exception of low-nanomolar pyrazolopyridine calcitonin
receptor partial agonists (33), class B GPCR agonist mol-
ecules have micromolar potencies. Much activity has been
expended searching for GLP-1 receptor small molecule
agonists, and up to this point, only two bona ﬁde agonists
have been described: low molecular weight substituted
quinoxalines (13–16) and the large cyclobutane derivative,
Boc-5 (17). Boc-5 is described as an orthosteric agonist,
but it likely does not have suitable physiochemical prop-
erties to be developed as an orally available GLP-1 recep-
tor agonist. The quinoxaline compounds exhibit some
chemical similarity to the pyrimidines described in this
report. The mechanism of action of the substituted qui-
noxalines appears to be analogous to compound B. Both
molecules exhibit agonist and positive allosteric modula-
tor activity at the GLP-1 receptor, and neither competes
with GLP-1 for receptor binding (13). We probed the
structural determinants of compound B interaction with
the GLP-1 receptor using a functional GLP-1 receptor
variant lacking the ECD (–ECD-GLP-1 receptor). Inter-
estingly, we observed that compound B action is indepen-
dent of the GLP-1 receptor ECD, implying that compound
B probably acts proximal to the transmembrane domains
of the GLP-1 receptor, similar to the mechanism used by
canonical small molecule agonists and allosteric modula-
tors for class A and class C GPCRs (35). Further determi-
nants of compound B interaction with the GLP-1 receptor
have not been fully elucidated. Recent studies have de-
ﬁned the structure of the GLP-1 peptide-bound ECD of the
GLP-1 receptor (36,37). However, there is little additional
structural data to guide targeted design of low molecular
weight agonists for the GLP-1 receptor, especially with
regard to understanding and possibly exploiting critical
transmembrane domains to modulate signaling. Computa-
tional approaches have been used to generate hypotheses
B
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FIG. 7. Compound B enhances insulin secretion in normal and diabetic human islets. A: Insulin concentrations from static cultures of normal
human islets incubated in media containing high glucose (11.2 mmol/l) and either GLP-1 (100 nmol/l) or various concentrations of compound B
(1–10 mol/l). The treatments were performed for 90 min, and results are expressed as mean  SEM, *P < 0.05. In perifusion experiments, insulin
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molecule binding to the juxtamembrane regions of the
GLP-1 receptor (38). The quinoxaline series of GLP-1
receptor agonists is predicted to bind in a pocket formed
by the ﬁrst and second extracellular loops; however, these
predictions need to be conﬁrmed by mutagenesis studies
(38).
The discovery of pyrimidine-based GLP-1 receptor ago-
nists that induce glucose-dependent insulin secretion in
vitro and in vivo demonstrates that modulating class B
GPCRs with low molecular weight compounds is techni-
cally feasible. However, further work is needed to improve
potency and optimize pharmacokinetic properties of these
molecules to enable clinical development. Future studies
will also focus on characterizing the allosteric binding site
and ligand-mediated conformational changes induced by
compound B to potentiate receptor signaling. A better
understanding of the pocket and mechanism of activation
will facilitate molecular modeling strategies to develop
more potent small molecule GLP-1 receptor agonists.
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